<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="003d59d2-ec90-4e7e-8a80-89dfe69632c6"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution CII, </content>
      <content styleCode="bold">5 mg/5 mL  </content>
      <content styleCode="bold">Rx Only</content>
   </title>
   <effectiveTime value="20250326"/>
   <setId root="7658071e-ee2c-4d23-94ce-1906959ec036"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="120378264" root="1.3.6.1.4.1.519.1"/>
            <name>Cranbury Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="74b14b7f-8749-4570-a598-4542b1ef593c"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20231023"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="27808-085" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextroamphetamine</name>
                        <formCode code="C42986" displayName="SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextroamphetamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8SKN0B0MIM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZOIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FST467XS7D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SACCHARIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="473"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="27808-085-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130531"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203644" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20130531"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>clear colorless</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73368" displayName="BUBBLE GUM" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_00d11da0-1621-4f95-898a-1ab0cf45decb">
               <id root="69faa23b-bd56-4231-a7aa-392c8f6e7e31"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: ABUSE, MISUSE, AND ADDICTION</content>
                  <br/>
               </title>
               <text>
                  <content styleCode="bold">Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see <linkHtml href="#www.splportal.comLINK_4def31a7-af53-4eef-ae80-5add893a7fc9">OVERDOSAGE</linkHtml>), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.<br/>
                     <br/>Before prescribing dextroamphetamine sulfate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine sulfate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>, <linkHtml href="#www.splportal.comLINK_39ca51a8-75bb-4faf-866b-e8d97764e1b3">DRUG ABUSE AND DEPENDENCE</linkHtml>).</content>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20231023"/>
            </section>
         </component>
         <component>
            <section ID="LINK_6b71f9d8-8097-48d9-9a37-0719357d1e05">
               <id root="71f303e4-36fa-4f80-9415-e3f413c63ab2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">DESCRIPTION </content>
               </title>
               <text>
                  <paragraph>Dextroamphetamine sulfate, USP is the dextro isomer of the compound<content styleCode="italics"> d,l</content>-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is <content styleCode="italics">d</content>-alpha-methylphenethylamine, and is present in all forms of dextroamphetamine sulfate as the neutral sulfate.</paragraph>
                  <paragraph>Structural Formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Dextroamphetamine sulfate, USP is a colorless, bubble gum flavored oral solution. Each 5 mL (1 teaspoonful) of dextroamphetamine sulfate oral solution contains 5 mg of dextroamphetamine sulfate. Inactive ingredients consist of anhydrous citric acid, benzoic acid, bubble gum flavor, purified water, sodium citrate anhydrous, sodium saccharin, and sorbitol solution.</paragraph>
               </text>
               <effectiveTime value="20231023"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dextroamphetamine-sulfate-oral-solution-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d72690a0-3c06-4c29-bf55-52640fa7717f">
               <id root="daee7cec-f620-4334-86f3-b68e9de86f7a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY
</content>
               </title>
               <text>
                  <paragraph>Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.</paragraph>
                  <paragraph>There is neither specific evidence that clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.</paragraph>
               </text>
               <effectiveTime value="20231023"/>
               <component>
                  <section ID="LINK_5993ad6a-8111-4263-ba40-ad964368b084">
                     <id root="a7ee0005-4707-4b67-8538-122737fb3093"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">Pharmacokinetics
</content>
                     </title>
                     <text>
                        <paragraph>Ingestion of 10 mg of dextroamphetamine sulfate in oral solution form by healthy volunteers produced an average peak dextroamphetamine blood level of 33.2 ng/mL. The half-life was 11.75 hours. The average urinary recovery was 38% in 48 hours.</paragraph>
                        <paragraph>In 12 healthy subjects, the rate and extent of dextroamphetamine absorption were similar following administration of the sustained release capsule formulation in the fed (58 to 75 gm fat) and fasted state.</paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8b9673f2-dedd-4046-8a70-34ffd91cdc78">
               <id root="25f760a7-eef0-41fa-bb7e-08435af7a6d8"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">INDICATIONS AND USAGE
</content>
               </title>
               <text>
                  <paragraph>Dextroamphetamine sulfate oral solution is indicated in:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Narcolepsy</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Attention Deficit Disorder with Hyperactivity: </content>As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.</paragraph>
               </text>
               <effectiveTime value="20231023"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d5e5cf98-898c-4e7f-bca3-723cf4dc78b9">
               <id root="55347567-436a-4634-80d7-abe702e09429"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">CONTRAINDICATIONS
</content>
               </title>
               <text>
                  <paragraph>Known hypersensitivity to amphetamine products. During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crisis may result).</paragraph>
               </text>
               <effectiveTime value="20231023"/>
            </section>
         </component>
         <component>
            <section ID="LINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">
               <id root="b55cf408-f95b-47b7-a202-0a347c3a8003"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>
                  <content styleCode="bold">WARNINGS </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph> Dextroamphetamine sulfate has a high potential for abuse and misuse. The use of dextroamphetamine sulfate exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Dextroamphetamine sulfate can be diverted for non-medical use into illicit channels or distribution (see <linkHtml href="#www.splportal.comLINK_39ca51a8-75bb-4faf-866b-e8d97764e1b3">DRUG ABUSE and DEPENDENCE</linkHtml>). Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see <linkHtml href="#www.splportal.comLINK_4def31a7-af53-4eef-ae80-5add893a7fc9">OVERDOSAGE</linkHtml>), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                  <paragraph>Before prescribing dextroamphetamine sulfate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give dextroamphetamine sulfate to anyone else. Throughout dextroamphetamine sulfate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended ADHD dosages.</paragraph>
                  <paragraph> Avoid Dextroamphetamine Sulfate Oral Solution use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Increased Blood Pressure and Heart Rate </content>
                  </paragraph>
                  <paragraph> CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for potential tachycardia and hypertension.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Psychiatric Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Exacerbation of Pre-Existing Psychosis: CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.</paragraph>
                  <paragraph>Induction of a Manic Episode in Patients with Bipolar Disorder: CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).</paragraph>
                  <paragraph>New Psychotic or Manic Symptoms: CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0% of placebo-treated patients. If such symptoms occur, consider discontinuing dextroamphetamine sulfate.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Long-Term Suppression of Growth in Pediatric Patients: </content>CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients, including dextroamphetamine sulfate. Closely monitor growth (weight and height) in Dextroamphetamine Sulfate Oral Solution-treated pediatric patients treated with CNS stimulants.</paragraph>
                  <paragraph>Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted (see <linkHtml href="#www.splportal.comLINK_724a25e6-cbb1-4a9e-8642-785b8804ec24">PRECAUTIONS</linkHtml>
                     <linkHtml href="#DRAFT%201.14.3.1%20Annotated%20Labeling%20Text%20Previously%20Submitted%20vs%20Proposed.docx#P_Pediatric_Use">, </linkHtml>
                     <linkHtml href="#www.splportal.comLINK_5444f4e2-d1a6-423b-9013-5d340c26fc3e">PEDIATRIC USE</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Seizures:</content> There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Peripheral Vasculopathy, Including Raynaud’s Phenomenon: </content>Stimulants, including dextroamphetamine sulfate oral solution, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulcerations and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. Careful observation for digital changes is necessary during dextroamphetamine sulfate oral solution-treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for dextroamphetamine sulfate oral solution-treated patients who develop signs or symptoms of peripheral vasculopathy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Serotonin Syndrome</content>
                     <content styleCode="bold">:</content> Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort (see <linkHtml href="#www.splportal.comLINK_f33054eb-c00a-49a3-b883-786365d6f8de">DRUG INTERACTIONS</linkHtml>
                     <content styleCode="bold">)</content>.</paragraph>
                  <paragraph>The coadministration with cytochrome P450 (CYP2D6) inhibitors may also increase the risk with increased exposure to dextroamphetamine sulfate oral solution. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 (see <linkHtml href="#www.splportal.comLINK_f33054eb-c00a-49a3-b883-786365d6f8de">DRUG INTERACTIONS</linkHtml>
                     <content styleCode="bold">)</content>.</paragraph>
                  <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).</paragraph>
                  <paragraph>Concomitant use of dextroamphetamine sulfate oral solution with MAOI drugs is contraindicated (see <linkHtml href="#www.splportal.comLINK_d5e5cf98-898c-4e7f-bca3-723cf4dc78b9">CONTRAINDICATIONS</linkHtml>
                     <content styleCode="bold">)</content>.</paragraph>
                  <paragraph>Discontinue treatment with dextroamphetamine sulfate oral solution and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of dextroamphetamine sulfate oral solution  with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate dextroamphetamine sulfate oral solution with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                  </paragraph>
                  <paragraph> CNS stimulants, including amphetamine sulfate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported. Assess the family history and clinically evaluate patients for tics or Tourette’s syndrome before initiating dextroamphetamine sulfate. Regularly monitor patients for the emergence or worsening of tics or Tourette’s syndrome with dextroamphetamine sulfate, and discontinue treatment if clinically appropriate.</paragraph>
               </text>
               <effectiveTime value="20231023"/>
            </section>
         </component>
         <component>
            <section ID="LINK_724a25e6-cbb1-4a9e-8642-785b8804ec24">
               <id root="9308bbeb-199c-4ebf-9ab1-eec3d6cb3b32"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">PRECAUTIONS
</content>
               </title>
               <effectiveTime value="20231023"/>
               <component>
                  <section ID="LINK_1ff41749-b054-4ae9-a8aa-f7c28706a3bf">
                     <id root="3d76931c-e084-44ce-9ffd-0c98f990b707"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>
                        <content styleCode="bold">Information for Patients</content>
                     </title>
                     <text>
                        <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Abuse, Misuse, and Addiction</content>
                        </paragraph>
                        <paragraph> Educate patients and their families about the risks of abuse, misuse, and addiction of dextroamphetamine sulfate which can lead to overdose and death, and proper disposal of any unused drug (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>, <linkHtml href="#www.splportal.comLINK_39ca51a8-75bb-4faf-866b-e8d97764e1b3">DRUG ABUSE AND DEPENDENCE</linkHtml>, and <linkHtml href="#www.splportal.comLINK_4def31a7-af53-4eef-ae80-5add893a7fc9">OVERDOSAGE</linkHtml>). Advise patients to store dextroamphetamine sulfate in a safe place, preferably locked, and instruct patients to not give dextroamphetamine sulfate to anyone else.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Risks to Patients with Serious Cardiac Disease</content>
                        </paragraph>
                        <paragraph> Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with dextroamphetamine sulfate use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Increased Blood Pressure and Heart Rate</content>
                        </paragraph>
                        <paragraph> Advise patients that dextroamphetamine sulfate can elevate blood pressure and heart rate (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Adverse Reactions</content>
                        </paragraph>
                        <paragraph> Advise patients that dextroamphetamine sulfate, at recommended doses, can cause psychotic or manic symptoms, even in patients without prior history of psychotic symptoms or mania (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Long-Term Suppression of Growth in Pediatric Patients</content>
                        </paragraph>
                        <paragraph> Advise patients that dextroamphetamine sulfate, may cause slowing of growth including weight loss (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud’s phenomenon]</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Instruct patients beginning treatment with dextroamphetamine sulfate oral solution about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.</item>
                           <item>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.</item>
                           <item>
                              <content styleCode="bold">Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking dextroamphetamine sulfate oral solution.</content>
                           </item>
                           <item>Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Serotonin Syndrome</content>
                           <br/>Caution patients about the risk of serotonin syndrome with concomitant use of dextroamphetamine sulfate and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort, and  with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid (see <linkHtml href="#www.splportal.comLINK_d5e5cf98-898c-4e7f-bca3-723cf4dc78b9">CONTRAINDICATIONS</linkHtml>, <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>, and <linkHtml href="#www.splportal.comLINK_f33054eb-c00a-49a3-b883-786365d6f8de">DRUG INTERACTIONS</linkHtml>). Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                        </paragraph>
                        <paragraph>Advise patients that motor and verbal tics and worsening of Tourette’s Syndrome may occur during treatment with dextroamphetamine sulfate. Instruct the patients to notify their healthcare provider if emergence or worsening of tics or Tourette’s syndrome occurs (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</paragraph>
                        <paragraph> Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f33054eb-c00a-49a3-b883-786365d6f8de">
               <id root="04da6697-314c-447b-872a-46b5d3063d12"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">Drug Interactions</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">MAO Inhibitors</content> - MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serotonergic Drugs</content> - The concomitant use of dextroamphetamine sulfate oral solution and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine sulfate oral solution initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine sulfate oral solution and the concomitant serotonergic drug(s) (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>, <linkHtml href="#www.splportal.comLINK_724a25e6-cbb1-4a9e-8642-785b8804ec24">PRECAUTIONS</linkHtml>
                     <content styleCode="bold">)</content>. Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort.</paragraph>
                  <paragraph>
                     <content styleCode="underline">CYP2D6 Inhibitors</content> - The concomitant use of dextroamphetamine sulfate oral solution and CYP2D6 inhibitors may increase the exposure of dextroamphetamine sulfate oral solution compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during dextroamphetamine sulfate oral solution initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine sulfate oral solution and the CYP2D6 inhibitor (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>, <linkHtml href="#www.splportal.comLINK_4def31a7-af53-4eef-ae80-5add893a7fc9">OVERDOSAGE</linkHtml>
                     <content styleCode="bold">)</content>. Examples of CYP2D6 Inhibitors include paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>
                     <content styleCode="underline">Acidifying Agents</content>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>– Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Adrenergic Blockers</content>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>– Adrenergic blockers are inhibited by amphetamines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Alkalinizing Agents</content>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>– Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antidepressants, Tricyclic</content> – Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antihistamines </content>– Amphetamines may counteract the sedative effect of antihistamines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antihypertensives</content> – Amphetamines may antagonize the hypotensive effects of antihypertensives.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Chlorpromazine</content> – Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Ethosuximide</content> – Amphetamines may delay intestinal absorption of ethosuximide.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Haloperidol </content>– Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lithium Carbonate</content> – The stimulatory effects of amphetamines may be inhibited by lithium carbonate.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Meperidine</content>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>– Amphetamines potentiate the analgesic effect of meperidine.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Methenamine Therapy</content> – Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Norepinephrine</content>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>– Amphetamines enhance the adrenergic effect of norepinephrine.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Phenobarbital </content>– Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Phenytoin</content> – Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Propoxyphene</content>
                     <content styleCode="bold">
                        <content styleCode="italics"> </content>
                     </content>– In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Veratrum Alkaloids</content> – Amphetamines inhibit the hypotensive effect of veratrum alkaloids.</paragraph>
               </text>
               <effectiveTime value="20231023"/>
               <component>
                  <section ID="LINK_ff3287b3-8345-4d32-8ad2-8c9228951ae7">
                     <id root="76340000-e98d-46ff-9186-35906deb0f82"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>
                        <content styleCode="bold">Drug/Laboratory Test Interactions</content>
                     </title>
                     <text>
                        <paragraph>Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.</paragraph>
                        <paragraph>Amphetamines may interfere with urinary steroid determinations.</paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_71c18d15-4bd0-4775-9dd7-a983006b3da7">
                     <id root="5af65f89-4358-45f6-8583-18b34640ab26"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">Carcinogenesis/Mutagenesis</content>
                     </title>
                     <text>
                        <paragraph>Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of dextroamphetamine sulfate have not been performed.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0c84207b-675f-4427-b3c0-458825b0b01a">
                     <id root="b936d3d2-a6d1-464c-a514-998a62c322ca"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <text/>
                     <effectiveTime value="20231023"/>
                     <component>
                        <section ID="LINK_b5d1c021-ebcf-415a-a7bc-d1e897050d55">
                           <id root="fe1ea072-2784-41d1-9994-6d9fa05d4380"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="underline">Teratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Pregnancy Category C</content>
                              </paragraph>
                              <paragraph> Dextroamphetamine sulfate has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose. Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose. While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenital bony deformity, tracheoesophageal fistula, and anal atresia (VATER association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Dextroamphetamine sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231023"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_63bc9832-fa57-4bdf-af79-e0a53de8e255">
                           <id root="d0dfa2e6-6fb6-4d6d-8aa4-edcff933c0b4"/>
                           <code code="34078-6" codeSystem="2.16.840.1.113883.6.1" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="underline">Nonteratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.<br/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231023"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a141cb4b-4831-4c73-95bf-2f513d455d7c">
                     <id root="671cfe9d-20c2-4139-a52d-8c840c997e85"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">Nursing Mothers</content>
                     </title>
                     <text>
                        <paragraph>Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5444f4e2-d1a6-423b-9013-5d340c26fc3e">
                     <id root="4e2de957-1102-4fbd-b609-6cd71734b959"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Long-term effects of amphetamines in pediatric patients have not been well established.</paragraph>
                        <paragraph>Amphetamines are not recommended for use in pediatric patients under 3 years of age with Attention Deficit Disorder with Hyperactivity described under <linkHtml href="#www.splportal.comLINK_8b9673f2-dedd-4046-8a70-34ffd91cdc78">INDICATIONS AND USAGE</linkHtml>.</paragraph>
                        <paragraph>Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.</paragraph>
                        <paragraph>Amphetamines have been reported to exacerbate motor and phonic tics and Tourette’s syndrome. Therefore, clinical evaluation for tics and Tourette’s syndrome in children and their families should precede use of stimulant medications.</paragraph>
                        <paragraph>Data are inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore, growth should be monitored during treatment.</paragraph>
                        <paragraph>Drug treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the child. The decision to prescribe amphetamines should depend on the physician’s assessment of the chronicity and severity of the child’s symptoms and their appropriateness for his or her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.</paragraph>
                        <paragraph>When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2d198a32-da3f-4083-9242-e7975deab743">
               <id root="dedefc08-3dad-4ef2-b6c6-111a0027b5bf"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">ADVERSE REACTIONS
</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular: </content>Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Central Nervous System: </content>Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and verbal tics and Tourette’s syndrome.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal: </content>Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Allergic: </content>Urticaria.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Endocrine: </content>Impotence, changes in libido.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Musculoskeletal:</content> Rhabdomyolysis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Cranbury Pharmaceuticals, LLC at 1-732-940-0358 or FDA at 1-800-FDA-1088 or <content styleCode="bold">
                           <linkHtml href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">www.fda.gov/medwatch</linkHtml>
                        </content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250324"/>
            </section>
         </component>
         <component>
            <section ID="LINK_39ca51a8-75bb-4faf-866b-e8d97764e1b3">
               <id root="08becca4-4f8e-4ec7-b2da-0f271fb3abe2"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>
                  <content styleCode="bold">DRUG ABUSE AND DEPENDENCE
</content>
               </title>
               <text/>
               <effectiveTime value="20231023"/>
               <component>
                  <section ID="LINK_b26962a1-edf9-4a39-92fe-625b1155e02a">
                     <id root="de1f53e1-1e45-43c9-8c1c-cca0c407e912"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Controlled Substance</content>
                     </title>
                     <text>
                        <paragraph>Dextroamphetamine sulfate is a Schedule II controlled substance.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e38572f6-596f-4111-a6ba-f74cc96dad11">
                     <id root="8b15a8e0-8de3-42e7-8528-3cdd23247bee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Abuse</content>
                     </title>
                     <text>
                        <paragraph>Dextroamphetamine sulfate has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>). Dextroamphetamine sulfate can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                        <paragraph> Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                        <paragraph>Misuse and abuse of amphetamines may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including Dextroamphetamine sulfate, can result in overdose and death (see <linkHtml href="#www.splportal.comLINK_4def31a7-af53-4eef-ae80-5add893a7fc9">OVERDOSAGE</linkHtml>), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_386dab71-56c8-47bd-90b6-29a708c9d3f5">
                     <id root="8004eb67-738d-4d26-9e36-283adae30e08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Dependence</content>
                     </title>
                     <text>
                        <paragraph>Physical Dependence</paragraph>
                        <paragraph>Dextroamphetamine sulfate may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph> Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including Dextroamphetamine sulfate include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                        <paragraph>Tolerance</paragraph>
                        <paragraph> Dextroamphetamine sulfate may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
                     </text>
                     <effectiveTime value="20231023"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4def31a7-af53-4eef-ae80-5add893a7fc9">
               <id root="53926588-31cd-46f1-9c77-a5f55fbe51a9"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">OVERDOSAGE
</content>
               </title>
               <text>
                  <paragraph>Clinical Effects of Overdose</paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                     <item>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                     <item>Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.</item>
                  </list>
                  <paragraph>Overdose Management</paragraph>
                  <paragraph> Consider the possibility of multiple drug ingestion. D-amphetamine is not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20231023"/>
            </section>
         </component>
         <component>
            <section ID="LINK_93c5fe6a-a072-4827-a008-9d63f7e2ab8a">
               <id root="f5e71840-d9b8-4de7-8cfb-2e0b73cf0ee5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION
</content>
               </title>
               <text>
                  <paragraph>Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Narcolepsy: </content>Usual dose is 5 mg to 60 mg per day in divided doses, depending on the individual patient response.</paragraph>
                  <paragraph>Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate oral solution may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Attention Deficit Disorder with Hyperactivity: </content>Not recommended for pediatric patients under 3 years of age.</paragraph>
                  <paragraph>
                     <content styleCode="bold">In pediatric patients from 3 to 5 years of age, </content>start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.</paragraph>
                  <paragraph>
                     <content styleCode="bold">In pediatric patients 6 years of age and older, </content>start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day.</paragraph>
                  <paragraph>Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.</paragraph>
                  <paragraph>Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.</paragraph>
                  <paragraph>Prior to treating patients with dextroamphetamine sulfate assess:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</item>
                     <item>the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome (see <linkHtml href="#www.splportal.comLINK_2fee12d9-2c9c-4a56-87b4-2729fa546099">WARNINGS</linkHtml>).</item>
                  </list>
               </text>
               <effectiveTime value="20231023"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9232ed39-d51a-4768-8077-f3c90d953329">
               <id root="3597468e-bdcf-41a2-b59f-af88e1b52996"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">HOW SUPPLIED </content>
               </title>
               <text>
                  <paragraph>Dextroamphetamine Sulfate Oral Solution 5 mg/5 mL is a colorless, bubble gum flavored oral solution. It is available in 16 fluid ounces (473 mL) bottles, NDC 27808-085-01.</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container with a child-resistant closure.</paragraph>
                  <paragraph>Manufactured by</paragraph>
                  <paragraph>
                     <content styleCode="bold">Tris Pharma, Inc.</content>
                  </paragraph>
                  <paragraph>Monmouth Junction, NJ 08852</paragraph>
                  <paragraph>For:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cranbury Pharmaceuticals, LLC</content>
                  </paragraph>
                  <paragraph>Monmouth Junction, NJ 08852</paragraph>
                  <paragraph>LB8255</paragraph>
                  <paragraph>Rev.10</paragraph>
                  <paragraph>Revised: 08/2024</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="LINK_0a6f6905-2320-4128-9c3a-92712bd984dd">
               <id root="dfb74e71-5461-46d5-b7f5-433c106a7fee"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>
                  <content styleCode="bold">MEDICATION GUIDE</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution, </content>
                     </content>
                     <content styleCode="bold">CII 5 mg/5 mL</content>
                  </paragraph>
                  <paragraph>(DEX-troe-am-FET-a-meen SUL-fate)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <table>
                     <col/>
                     <tbody>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about Dextroamphetamine Sulfate Oral Solution?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Abuse, misuse, and addiction. </content>Dextroamphetamine Sulfate Oral Solution has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Dextroamphetamine Sulfate Oral Solution, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of Dextroamphetamine Sulfate Oral Solution or when it is used in ways that are not approved, such as snorting or injection.
                <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with Dextroamphetamine Sulfate Oral Solution and will monitor you or your child during treatment. </item>
                                       <item>Dextroamphetamine Sulfate Oral Solution may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                       <item>Do not give Dextroamphetamine Sulfate Oral Solution to anyone else. See “<content styleCode="bold">What is Dextroamphetamine Sulfate Oral Solution?</content>” for more information.</item>
                                       <item>Keep Dextroamphetamine Sulfate Oral Solution in a safe place and properly dispose of any unused medicine. See “<content styleCode="bold">How should I store Dextroamphetamine Sulfate Oral Solution?</content>” for more information.</item>
                                       <item>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs. </item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Risks for people with serious heart disease: </content>Sudden death has happened in people who have heart defects or other serious heart disease. </item>
                              </list>
                              <paragraph>Your healthcare provider should check you or your child carefully for heart problems before starting treatment with Dextroamphetamine Sulfate Oral Solution. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Dextroamphetamine Sulfate Oral Solution.</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold"> </content>Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment with Dextroamphetamine Sulfate Oral Solution.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Mental (psychiatric) problems, including:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>new or worse behavior or thought problems</item>
                                       <item>new or worse bipolar illness</item>
                                       <item>new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems <content styleCode="bold">during treatment with</content> Dextroamphetamine Sulfate Oral Solution, especially <content styleCode="bold">hearing voices, </content>seeing or believing things that are not real, or <content styleCode="bold">new manic symptoms</content>.</content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What is Dextroamphetamine Sulfate Oral Solution?</content>
                  </paragraph>
                  <paragraph>Dextroamphetamine Sulfate Oral Solution is a central nervous system (CNS) stimulant prescription medicine used for the treatment of:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>a sleep disorder called narcolepsy.</item>
                     <item>Attention-Deficit Hyperactivity Disorder (ADHD) in children 6 to 17 years of age. </item>
                     <item>Dextroamphetamine Sulfate Oral Solution may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.</item>
                  </list>
                  <paragraph>It is not known if Dextroamphetamine Sulfate Oral Solution is safe and effective in children under 6 years of age.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution is a federally controlled substance (CII) because it contains dextroamphetamine that can be a target for people who abuse prescription medicines or street drugs.</content>  Keep Dextroamphetamine Sulfate Oral Solution in a safe place to protect it from theft. Never give your Dextroamphetamine Sulfate Oral Solution to anyone else because it may cause death or harm them. Selling or giving away Dextroamphetamine Sulfate Oral Solution may harm others, and is against the law.</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Do not take <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution if you or your child:</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>are allergic to amphetamine products or any of the ingredients in Dextroamphetamine Sulfate Oral Solution. See the end of this Medication Guide for a complete list of ingredients in Dextroamphetamine Sulfate Oral Solution.</item>
                     <item>are taking or have taken within the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI), including the antibiotic linezolid or the intravenous medicine methylene blue.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before taking <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution, tell your healthcare provider <content styleCode="bold">about all of your or your child’s medical conditions, </content>
                        </content>
                     </content>
                     <content styleCode="bold">including if you or your child:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>have heart problems, heart disease, heart defects, or high blood pressure</item>
                     <item>have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression</item>
                     <item>have seizures or have had an abnormal brain wave test (EEG)</item>
                     <item>have circulation problems in fingers and toes</item>
                     <item>have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome</item>
                     <item>are pregnant or plan to become pregnant. It is not known if Dextroamphetamine Sulfate Oral Solution will harm the unborn baby. Tell your healthcare provider if you or your child become pregnant during treatment with Dextroamphetamine Sulfate Oral Solution.</item>
                     <item>are breastfeeding or plan to breastfeed. Dextroamphetamine Sulfate Oral Solution passes into breast milk. You or your child should not breastfeed during treatment with Dextroamphetamine Sulfate Oral Solution. Talk to your healthcare provider about the best way to feed the baby during treatment with Dextroamphetamine Sulfate Oral Solution.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all of the medicines that you or your child take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph> Dextroamphetamine Sulfate Oral Solution and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with Dextroamphetamine Sulfate Oral Solution. Your healthcare provider will decide if Dextroamphetamine Sulfate Oral Solution can be taken with other medicines.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Especially tell your healthcare provider if you or your child take:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>selective serotonin reuptake inhibitors (SSRIs)</item>
                     <item>medicines used to treat migraine headaches called triptans</item>
                     <item>lithium</item>
                     <item>tramadol</item>
                     <item>buspirone</item>
                     <item>serotonin norepinephrine reuptake inhibitors (SNRIs)</item>
                     <item>tricyclic antidepressants</item>
                     <item>fentanyl</item>
                     <item>tryptophan</item>
                     <item>St. John’s Wort</item>
                  </list>
                  <paragraph>Know the medicines that you or your child take. Keep a list of your or your child’s medicines with you to show your healthcare provider and pharmacist when you or your child get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not start any new medicine during treatment with Dextroamphetamine Sulfate Oral Solution without talking to your healthcare provider first.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should Dextroamphetamine Sulfate Oral Solution be taken?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold"> </content>Take Dextroamphetamine Sulfate Oral Solution exactly as prescribed by your or your child’s healthcare provider. </item>
                     <item>Your healthcare provider may change the dose if needed.</item>
                     <item> Dextroamphetamine Sulfate Oral Solution is usually taken two to three times a day. The first dose is usually taken in the morning. One or two more doses may be taken during the day, 4 to 6 hours apart.</item>
                  </list>
                  <paragraph>If you or your child take too much Dextroamphetamine Sulfate Oral Solution, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking Dextroamphetamine Sulfate Oral Solution?</content>
                  </paragraph>
                  <paragraph>Do not drive, operate heavy machinery, or do other potentially dangerous activities until you know how Dextroamphetamine Sulfate Oral Solution affects you.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are possible side effects of Dextroamphetamine Sulfate Oral Solution?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution may cause serious side effects, including:</content>
                  </paragraph>
                  <paragraph> See “<content styleCode="bold">What is the most important information I should know about Dextroamphetamine Sulfate Oral Solution?</content>”</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <paragraph>
                           <content styleCode="bold">Slowing of growth (height and weight) in children.</content> Children should have their height and weight checked often during treatment with Dextroamphetamine Sulfate Oral Solution. Your healthcare provider may stop your child’s Dextroamphetamine Sulfate Oral Solution treatment if they are not growing or gaining weight as expected.</paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">Seizures. </content>Your healthcare provider may stop treatment with Dextroamphetamine Sulfate Oral Solution if you or your child have a seizure<content styleCode="bold">.</content>
                        </paragraph>
                     </item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon).<br/>
    Signs and symptoms may include:</content>
                     </item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>fingers or toes may feel numb, cool, painful</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>fingers or toes may change color from pale, to blue, to red</item>
                  </list>
                  <paragraph>Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your healthcare provider right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with Dextroamphetamine Sulfate Oral Solution.</content>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">New or worsening tics or worsening Tourette’s syndrome. </content>Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with Dextroamphetamine Sulfate Oral Solution.</item>
                     <item>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Serotonin syndrome. </content>This problem may happen when Dextroamphetamine Sulfate Oral Solution is taken with certain other medicines and may be life-threatening. Stop taking Dextroamphetamine Sulfate Oral Solution and call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs and symptoms of serotonin syndrome:</item>
                  </list>
                  <list listType="unordered" styleCode="Circle">
                     <item>agitation</item>
                     <item>fast heartbeat</item>
                     <item>flushing </item>
                     <item>seizures</item>
                     <item>coma</item>
                     <item>sweating</item>
                     <item>loss of coordination</item>
                     <item>confusion</item>
                     <item>dizziness</item>
                     <item>tremors, stiff muscles, or muscle twitching </item>
                     <item>seeing or hearing things that are not real (hallucination)</item>
                     <item>changes in blood pressure</item>
                     <item>high body temperature (hypothermia)</item>
                     <item>nausea, vomiting, diarrhea</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of Dextroamphetamine Sulfate Oral Solution include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>fast heartbeat</item>
                     <item>decreased appetite</item>
                     <item>tremors</item>
                     <item>headache</item>
                     <item>trouble sleeping</item>
                     <item>dizziness</item>
                     <item>stomach upset</item>
                     <item>weight loss</item>
                     <item>dry mouth</item>
                  </list>
                  <paragraph>These are not all of the possible side effects of Dextroamphetamine Sulfate Oral Solution. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store Dextroamphetamine Sulfate Oral Solution?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Store Dextroamphetamine Sulfate Oral Solution at room temperature between 68° to 77°F (20° to 25°C). </item>
                     <item>Store Dextroamphetamine Sulfate Oral Solution in a safe place, like a locked cabinet. Protect from light.</item>
                     <item>Dispose of remaining, unused, or expired Dextroamphetamine Sulfate Oral Solution by a medicine take-back program at a<content styleCode="underline"> </content>U.S. Drug Enforcement Administration (DEA) authorized collection site. If no takeback program or DEA authorized collector is available, mix Dextroamphetamine Sulfate Oral Solution with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away Dextroamphetamine Sulfate Oral Solution in the household trash. Visit <linkHtml href="http://">www.fda.gov/drugdisposal</linkHtml> for additional information on disposal of unused medicines.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep Dextroamphetamine Sulfate Oral Solution and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of Dextroamphetamine Sulfate Oral Solution.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Dextroamphetamine Sulfate Oral Solution for a condition for which it was not prescribed. Do not give Dextroamphetamine Sulfate Oral Solution to other people, even if they have the same symptoms that you or your child have. It may harm them and it is against the law. You can ask your healthcare provider or pharmacist for information about Dextroamphetamine Sulfate Oral Solution that is written for health professionals. </paragraph>
                  <paragraph>For more information about Dextroamphetamine Sulfate Oral Solution, please contact Cranbury Pharmaceuticals, LLC at 1-732-940-0358 or go to <linkHtml href="https://www.cranburypharma.com/products/">https://www.cranburypharma.com/products/</linkHtml>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in Dextroamphetamine Sulfate Oral Solution?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient:</content> dextroamphetamine sulfate</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content> anhydrous citric acid, benzoic acid, bubble gum flavor, purified water, sodium citrate anhydrous, sodium saccharin, and sorbitol solution.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Tris Pharma, Inc.<br/>
                     </content>Monmouth Junction, NJ 08852</paragraph>
                  <paragraph>For:<br/>
                     <content styleCode="bold">Cranbury Pharmaceuticals, LLC<br/>
                     </content>Monmouth Junction, NJ 08852</paragraph>
                  <paragraph>LB8256</paragraph>
                  <paragraph> Rev. 07</paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: 08/2024</paragraph>
                  <paragraph>Dispense with Medication Guide available at: <linkHtml href="https://www.cranburypharma.com/products/">https://www.cranburypharma.com/products/</linkHtml>
                  </paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="LINK_8478c9bc-f54a-4301-b1e0-8c9385caefc4">
               <id root="0420f3e5-b705-4696-8b79-d6588a7c7401"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Dextroamphetamine Sulfate Oral Solution CII</content>
                  </paragraph>
                  <paragraph>5 mg/ 5 mL</paragraph>
                  <paragraph>16 fl. oz. (473 mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST:</content> Dispense the accompanying Medication Guide to each patient.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>16 oz label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dextroamphetamine-sulfate-oral-solution-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>